Redeye: Enea - Next Growth Stratum

Report this content

Redeye maintains its valuation and positive view of Enea, following our estimate changes yesterday. Shares still trade at a meager 13X EV/EBIT 21E. We raise our sight, beyond the Corona crisis, and expect the Stratum deal of USD 15-20m to drive solid growth from 2021.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.